Proactive Investors - Run By Investors For Investors

Indivior falls again as US court ruling clears way for launch of Suboxone generic

Suboxone is Indivor’s big money-maker, but two generic versions could hit the market as early as next Tuesday after the latest ruling from a US appeals court
suboxone
Indivior is adamant that the generics infringe on its patents and is taking its case to the Supreme Court

Indivior PLC (LON:INDV) has been dealt another blow in its bid to protect its star drug after a US court ruling cleared the way for two rivals to launch their generic versions of the opioid addiction next week.

The drugmaker has been aggressively defending Suboxone, which makes up the bulk of its annual revenue, for several years now, claiming that cut-price treatments from Dr Reddy’s and Alvogen infringe on its patents.

READ: Federal court rejects Suboxone appeal

But last week, a US appeals court ratified an earlier decision by a district court in Delaware that gave the generics the all-clear.

Indivior is taking its case to the Supreme Court, the highest court in the US, and had hoped to delay the launch of the copycat versions until after then.

But that request has been rejected by the appeals court, which has told Indian giant Dr Reddy’s and Alvogen that they can start selling their drugs into the market next Tuesday (19 February).

Dr Reddy’s not averse to an ‘at-risk’ launch

Any launch would be on an ‘at-risk’ basis though – when litigation is still going – as Indivior is still trying to protect its intellectual property (IP) through a court in New Jersey as well as the Supreme Court.

That wasn’t a concern for Dr Reddy’s last summer though when it briefly launched its version ‘at-risk’ and took a decent chunk out of Suboxone’s market share despite only being available for a few hours.

Indivior shares were down 2.2% to 104.7p. Last summer they were changing hands for more than 500p.

View full INDV profile View Profile

Indivior Timeline

Article
September 23 2016

Related Articles

PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use